{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:25:59Z","timestamp":1740126359978,"version":"3.37.3"},"reference-count":21,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2018,5,30]],"date-time":"2018-05-30T00:00:00Z","timestamp":1527638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Fundamemntal Clinical Pharma"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Isolated arthralgia, without hemorrhagic side effect, exists and is considered as a very rare adverse drug reaction according to vitamin K antagonists\u2019 (VKAs) summary of product characteristics. Up to now, there are no literature reports of isolated, nonhemorrhagic joint complications in patients receiving VKAs. Hence, the objective of this study was to describe cases of VKA\u2010related nonhemorrhagic joint disorders (fluindione, warfarin, and acenocoumarol) reported in the French Pharmacovigilance Database (FPVD). Sixty\u2010one reports (male : female ratio, 1.18; median [interquartile range (IQR)] age: 60 [49\u201372]) were found. Fluindione, warfarin, and acenocoumarol were respectively suspected in 42, 12, and 7 cases. Arthralgia was reported in 47 cases (77%), arthritis in nine cases (15%), capsulitis in three cases (5%), and bursitis in two cases (3%). Although the joint symptoms mainly concerned the lower limbs, all types of joints were affected. Arthralgia was associated with myalgia in 14 cases and with tendinitis in three cases. The median (IQR) time interval between VKA introduction and arthralgia onset was 26 (10\u201398) days (range: 1\u20136935). VKA was withdrawn in 44 cases, and a decrease in the intensity of joint symptoms was observed in 30 cases. In three cases, reintroduction of the same VKA led to the recurrence of symptoms. In view of the large prescription of this drug class worldwide, patients and clinicians (and especially primary care physicians and geriatricians) should be aware of this possible adverse drug reaction when confronted with joint disorders in patients of all ages taking VKAs.<\/jats:p>","DOI":"10.1111\/fcp.12380","type":"journal-article","created":{"date-parts":[[2018,5,5]],"date-time":"2018-05-05T19:14:44Z","timestamp":1525547684000},"page":"663-668","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Nonhemorrhagic joint disorders and vitamin K antagonists: an under\u2010recognized adverse drug reaction?"],"prefix":"10.1111","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1137-1830","authenticated-orcid":false,"given":"Johana","family":"B\u00e9n\u00e9","sequence":"first","affiliation":[{"name":"CHU Lille Centre R\u00e9gional de Pharmacovigilance du Nord\u2010Pas de Calais F\u201059000 Lille France"},{"name":"Universit\u00e9 de Lille 2 U1171, F\u201059000 Lille France"},{"name":"INSERM U1171 F\u201059000 Lille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9mentine","family":"Rousselin","sequence":"additional","affiliation":[{"name":"UFR de M\u00e9decine Universit\u00e9 de Lille F\u201059000 Lille France"},{"name":"CHU de Lille Service de M\u00e9decine Interne F\u201059000 Lille France"},{"name":"CHU de Lille Centre National De R\u00e9f\u00e9rence Maladies Syst\u00e9miques et Auto\u2010Immunes Rares (Scl\u00e9rodermie Syst\u00e9mique) F\u201059000 Lille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haleh","family":"Bagheri","sequence":"additional","affiliation":[{"name":"Service de Pharmacologie M\u00e9dicale et Clinique Centre Hospitalier Universitaire et Facult\u00e9 de M\u00e9decine de Toulouse 31000 Toulouse France"},{"name":"Facult\u00e9 de M\u00e9decine INSERM UMR 1027 Universit\u00e9 de Toulouse 31000 Toulouse France"},{"name":"Centre Midi\u2010Pyr\u00e9n\u00e9es de PharmacoVigilance de Pharmaco \u00e9pid\u00e9miologie et d'Informations sur le M\u00e9dicament et Pharmacop\u00f4le Midi\u2010Pyr\u00e9n\u00e9es 31000 Toulouse France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Vial","sequence":"additional","affiliation":[{"name":"Centre R\u00e9gional de Pharmacovigilance de Lyon Hospices Civils de Lyon 69000 Lyon France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Gautier","sequence":"additional","affiliation":[{"name":"CHU Lille Centre R\u00e9gional de Pharmacovigilance du Nord\u2010Pas de Calais F\u201059000 Lille France"},{"name":"Universit\u00e9 de Lille 2 U1171, F\u201059000 Lille France"},{"name":"INSERM U1171 F\u201059000 Lille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Lambert","sequence":"additional","affiliation":[{"name":"UFR de M\u00e9decine Universit\u00e9 de Lille F\u201059000 Lille France"},{"name":"CHU de Lille Service de M\u00e9decine Interne F\u201059000 Lille France"},{"name":"CHU de Lille Centre National De R\u00e9f\u00e9rence Maladies Syst\u00e9miques et Auto\u2010Immunes Rares (Scl\u00e9rodermie Syst\u00e9mique) F\u201059000 Lille France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,5,30]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"ANSM.Les anticoagulants en France en 2014: \u00e9tat des lieux synth\u00e8se et surveillance 2014 ansm.sante.fr."},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2292"},{"key":"e_1_2_8_4_1","first-page":"2154","volume-title":"Monographie PREVISCAN\u00ae (fluindione)","author":"Vidal L.D.","year":"2016"},{"key":"e_1_2_8_5_1","first-page":"618","volume-title":"Monographie COUMADINE\u00ae (warfarine)","author":"Vidal L.D.","year":"2016"},{"key":"e_1_2_8_6_1","first-page":"2515","volume-title":"Monographie SINTROM\u00ae MINISINTROM\u00ae (acenocoumarol)","author":"Vidal L.D.","year":"2016"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr500"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1159\/000185636"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2016.02.029"},{"key":"e_1_2_8_10_1","first-page":"557","article-title":"French pharmacovigilance database system:examples of utilisation","volume":"50","author":"Moore N.","year":"1995","journal-title":"Therapie"},{"key":"e_1_2_8_11_1","unstructured":"World Health Organisation.International drug monitoring: the role of national centres. [Online].1972. Accessed on 15\/12\/17. Available at:https:\/\/www.who-umc.org\/media\/2680\/who-technical-report-498.pdf."},{"key":"e_1_2_8_12_1","first-page":"111","article-title":"Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France","volume":"40","author":"Begaud B.","year":"1985","journal-title":"Therapie"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199920020-00002"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.acvd.2010.11.012"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000078468.11849.66"},{"key":"e_1_2_8_16_1","first-page":"347","article-title":"Mobilisation pour les antivitamines K","volume":"12","author":"Drouet L.","year":"2000","journal-title":"Sang Thromb. Vaiss."},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0755-4982(04)98748-9"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1699-0463.1994.tb05226.x"},{"key":"e_1_2_8_19_1","unstructured":"VigiLyze.Search and analyse VigiBase the WHO global database of Individual Case Safety Report (ICSRs)[Internet]. Accessed on March 2018. Available at:https:\/\/vigilyze.who-umc.org."},{"key":"e_1_2_8_20_1","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1001\/jama.288.13.1588","article-title":"Rates of spontaneous reporting of adverse drug reactions in France","volume":"288","author":"Begaud B.","year":"2002","journal-title":"JAMA"},{"key":"e_1_2_8_21_1","unstructured":"Portail de signalement des \u00e9v\u00e8nements sanitaires ind\u00e9sirables. [Online]. Accessed on 11\/27\/17. Available at:https:\/\/signalement.social-sante.gouv.fr\/psig_ihm_utilisateurs\/index.html#\/accueil."},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/09581596.2017.1329520"}],"container-title":["Fundamental &amp; Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ffcp.12380","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/fcp.12380","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T15:06:56Z","timestamp":1694876816000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/fcp.12380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,30]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1111\/fcp.12380"],"URL":"https:\/\/doi.org\/10.1111\/fcp.12380","archive":["Portico"],"relation":{},"ISSN":["0767-3981","1472-8206"],"issn-type":[{"type":"print","value":"0767-3981"},{"type":"electronic","value":"1472-8206"}],"subject":[],"published":{"date-parts":[[2018,5,30]]},"assertion":[{"value":"2018-01-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}